Estimated SARS-CoV-2 Seroprevalence in US Patients Receiving Dialysis 1 Year After the Beginning of the COVID-19 Pandemic
This article has been Reviewed by the following groups
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
SciScore for 10.1101/2021.03.07.21252786: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: The study received Institutional Review Board Approval from Stanford University. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:The limitations include lack of data on SARS-CoV-2 rtPCR testing or COVID19 symptoms, and relative under-sampling from the Northeast region. In summary, …
SciScore for 10.1101/2021.03.07.21252786: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: The study received Institutional Review Board Approval from Stanford University. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:The limitations include lack of data on SARS-CoV-2 rtPCR testing or COVID19 symptoms, and relative under-sampling from the Northeast region. In summary, using unbiased data from a sentinel population, we estimate that fewer than one in four persons in the US had evidence of SARS-CoV-2 antibody in January 2021, well below the level needed to confer herd immunity. Residents of majority minority and poorer neighborhoods, and younger age groups have substantially higher prevalence of SARS-CoV-2 antibodies. Since these sub-populations overlap with persons expressing high levels of vaccine hesitancy in the US24,25, vaccination campaigns will need to engage these high-risk groups in order to achieve sufficient penetration to reach community-level protection against SARS-CoV-2.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
